Royalty Pharma plc Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2019 to Q3 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Royalty Pharma plc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2019 to Q3 2024.
- Royalty Pharma plc Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was $544M, a 654% increase year-over-year.
- Royalty Pharma plc Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was $1.15B, a 521% increase year-over-year.
- Royalty Pharma plc annual Net Income (Loss) Attributable to Parent for 2023 was $1.13B, a 2550% increase from 2022.
- Royalty Pharma plc annual Net Income (Loss) Attributable to Parent for 2022 was $42.8M, a 93.1% decline from 2021.
- Royalty Pharma plc annual Net Income (Loss) Attributable to Parent for 2021 was $620M, a 36.4% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)